Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2008

View Archived Issues

AstraZeneca reports full year 2007 R&D highlights

GeoVax Clade B DNA/MVA HIV/AIDS vaccine to proceed to phase II

VICTOR-E1 data show sustained viral suppression with vicriviroc in HIV patients

FDA grants approval to Diamyd to initiate phase I trial of NP-2 for chronic pain

Raltegravir efficacy maintained through 48 weeks in BENCHMRK studies

Icagen announces completion of investment by Pfizer

NRDL and Lilly sign drug development agreement spanning multiple therapeutic areas

AnGes reports results from phase II clinical trials of ointment for atopic dermatitis

New therapeutic agents for cardiovascular disorders reported in recent patent literature

Novel immunomodulators disclosed in recent patents

Low-dose arm continues to be tested in phase III MDP 301 trial of Indevus' PRO-2000

EMEA recommends that new warnings be included in product information for Novartis' Sebivo

Can-Fite doses first cohort of patients in phase I CF-102 trial

FDA grants fast track status to levodopa/carbidopa intestinal gel

LAT-967 shows potential for AD by inducing Sp1 degradation

Takeda discontinues matuzumab development

Agonist-induced CCR5 internalization, an alternative mechanism to prevent HIV infection

Lundbeck initiates enrollment in phase II clinical study of Lu-AA-34893 for bipolar disorder

Recent patents describe novel compounds for the treatment of cancer

Activation of osteoblast GPCRs potentially useful as bone repair therapy

FDA approves Xyzal oral solution for the relief of allergies and urticaria

Newron completes enrollment in phase II study of ralfinamide in post-op dental pain

Bayer and Onyx terminate clinical phase III Nexavar study in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...